生命科学资讯

'Turning around the Titanic': How the incoming PBM reforms will transform CMS

What's driving health tech M&A

China startup AccurEdit raises $75M for gene editing therapies

Daiichi ends work on an ADC; Layoffs at GSK's R&D unit

Ultragenyx unwraps data that may be central to its gene therapy resubmission

Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings

Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months

AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo

Carbon Health files for bankruptcy, seeking to sell or restructure

First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?

New CagriSema data show improvement over semaglutide

GSK returns rights to Wave's RNA editing program for AATD

Spring Health acquires Alma, expanding insurance reach in virtual mental health

Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT

FDA rejects Aquestive's allergy drug over packaging issues

FDA opens submissions for PreCheck program to speed up US factory builds

SanegeneBio licenses RNAi candidate to Genentech for $200M upfront

Pharming’s immunodeficiency drug gets CRL for use in younger patients

European law changes mean drugmakers may have to grapple with generic competition sooner

Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more